Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
Central Laboratory of Advanced Diagnosis and Biomedical Research, Palermo, Italy.
Curr Oncol. 2020 Apr;27(2):e75-e80. doi: 10.3747/co.27.5293. Epub 2020 May 1.
Nivolumab is an anti-PD-1 antibody that restores the antitumour immune function of T cells, blocking the binding of PD-1 with its ligand PD-L1. PD-1 is expressed on T cells and interacts with PD-L1 on tumour cells. The PD-1-PD-L1 link inhibits T cell activation. In metastatic melanoma, PD-1-PD-L1 binding plays a critical role, and the advent of the immune checkpoint inhibitor nivolumab has delivered new and effective treatment options with proven clinical benefit. In the present study, we evaluated the efficacy of nivolumab in elderly patients with metastatic melanoma.
The study enrolled 55 elderly patients (75 years of age and older) with a diagnosis of metastatic melanoma. Primary endpoints of the study were progression-free survival (pfs) and the objective response rate; secondary endpoints were overall survival, reduction in serum lactate dehydrogenase (ldh) from before to after treatment, and tolerability.
Nivolumab was well tolerated and resulted in good disease control, with a manageable toxicity profile and significant clinical benefit. The duration of pfs was 5.1 months (95% confidence interval: 3.5 months to 6.8 months). A significant correlation was observed between reduction in serum ldh and pfs: 0.60 (95% confidence interval: 0.28 to 0.86; = 0.002).
Nivolumab is an immunotherapy treatment that has proved to be an effective and well-tolerated therapeutic option in elderly patients with metastatic melanoma.
纳武单抗是一种抗 PD-1 抗体，可恢复 T 细胞的抗肿瘤免疫功能，阻止 PD-1 与其配体 PD-L1 结合。PD-1 在 T 细胞上表达，并与肿瘤细胞上的 PD-L1 相互作用。PD-1-PD-L1 连接抑制 T 细胞激活。在转移性黑色素瘤中，PD-1-PD-L1 结合起着关键作用，免疫检查点抑制剂纳武单抗的出现为转移性黑色素瘤患者提供了新的、有效的治疗选择，并已证实具有临床获益。本研究评估了纳武单抗在老年转移性黑色素瘤患者中的疗效。
该研究纳入了 55 名被诊断为转移性黑色素瘤的老年患者（年龄 75 岁及以上）。研究的主要终点为无进展生存期（pfs）和客观缓解率；次要终点为总生存期、治疗前后血清乳酸脱氢酶（ldh）的降低情况和耐受性。
纳武单抗耐受性良好，疾病控制效果良好，具有可管理的毒性特征和显著的临床获益。pfs 为 5.1 个月（95%置信区间：3.5 个月至 6.8 个月）。治疗前后血清 ldh 的降低与 pfs 呈显著相关性：0.60（95%置信区间：0.28 至 0.86； = 0.002）。
纳武单抗是一种免疫疗法，已被证明是老年转移性黑色素瘤患者有效且耐受良好的治疗选择。
